Reports Q2 adjusted EBITDA C$15.37M vs. C$10.14M last year. “Aurora’s quarterly performance highlights our continued focus on profitable growth. We achieved record net revenue1 for global medical cannabis representing a 15% year-over-year increase, while adjusted EBITDA1 rose 52%. These strong results affirm our strategic prioritization of medical cannabis as the industry’s most compelling growth area,” said Executive Chairman and Chief Executive Officer, Miguel Martin.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Options Volatility and Implied Earnings Moves This Week, November 03 – November 07, 2025
- Aurora Cannabis Schedules Q2 2026 Investor Conference Call
- Video: Merus jumps after deal to be bought, MoonLake sinks after trial data
- Cannabis Stocks Jump as Trump Endorses Cannabidiol for Elderly Care
- Tilray up after Trump posts video on medical benefits of CBD for seniors